- Home
- IONS vs NNN Comparison
IONS vs NNN Comparison
Compare IONS & NNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NNN
- Stock Information
- Founded
- IONS 1989
- NNN 1984
- Country
- IONS United States
- NNN United States
- Employees
- IONS N/A
- NNN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NNN Real Estate Investment Trusts
- Sector
- IONS Health Care
- NNN Real Estate
- Exchange
- IONS Nasdaq
- NNN Nasdaq
- Market Cap
- IONS 6.8B
- NNN 7.8B
- IPO Year
- IONS 1991
- NNN N/A
- Fundamental
- Price
- IONS $69.15
- NNN $42.50
- Analyst Decision
- IONS Strong Buy
- NNN Hold
- Analyst Count
- IONS 18
- NNN 8
- Target Price
- IONS $72.83
- NNN $44.29
- AVG Volume (30 Days)
- IONS 2.2M
- NNN 1.3M
- Earning Date
- IONS 11-05-2025
- NNN 11-04-2025
- Dividend Yield
- IONS N/A
- NNN 5.60%
- EPS Growth
- IONS N/A
- NNN N/A
- EPS
- IONS N/A
- NNN 2.10
- Revenue
- IONS $944,050,000.00
- NNN $894,702,000.00
- Revenue This Year
- IONS $24.01
- NNN $5.26
- Revenue Next Year
- IONS $4.06
- NNN $4.00
- P/E Ratio
- IONS N/A
- NNN $20.39
- Revenue Growth
- IONS 16.05
- NNN 4.82
- 52 Week Low
- IONS $23.95
- NNN $35.80
- 52 Week High
- IONS $69.25
- NNN $49.57
- Technical
- Relative Strength Index (RSI)
- IONS 80.12
- NNN 49.54
- Support Level
- IONS $61.03
- NNN $42.43
- Resistance Level
- IONS $63.18
- NNN $43.39
- Average True Range (ATR)
- IONS 1.63
- NNN 0.53
- MACD
- IONS 0.02
- NNN 0.03
- Stochastic Oscillator
- IONS 89.41
- NNN 42.60
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NNN NNN REIT Inc.
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue. The maximum of the company's properties are located in the South and Southeast of the United States.